The “EMBRACE” Trial: Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus “Treatment of Physician’s Choice” in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
NCT00388726, EU CTR 2006-001949-34
May 2009 - Jun 2013
Overall Survival [ Time Frame: From date of randomization until death from any cause ]
Defined as the time from the date of randomization until the date of death from any cause.
Adult females (age 18+ years)
Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia (Hrvatska), Czechia, France, Hungary, Italy, Poland, Russian Federation, South Africa, Spain, Switzerland, United States See moreSee less
The CSR synopses contained on this website are from clinical trials sponsored by Eisai and are provided for informational purposes only. These summaries contain data from the specific study population but do not include the patient-level data from each study participant. The results reported in any single trial may not reflect the overall potential risks or benefits associated with Eisai’s products.
Only health care professionals may determine if a specific product is appropriate as a treatment option for a particular patient. Health care professionals should refer to the specific labelling information approved in their country when making prescribing decisions.
The information provided is not intended to commercialize or promote Eisai’s products for any unapproved uses.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information contained on this website. Eisai reserves the right to amend any information on this website at any time at its sole discretion.
No download available
Publication reference citation
Cortes J, O’Shaughnessy J, Loesch D, Twelves C, EMBRACE Eisai MB. Eribulin monotherapy versus
treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377(9769):914-923.
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
Redacted documents are available upon request for this study.